AVEO Pharmaceuticals, Inc. total revenue, net income and dynamics of changes in US dollar today
Net revenue AVEO Pharmaceuticals, Inc. is now 1 920 000 $. Information about net revenue is taken from open sources. The dynamics of AVEO Pharmaceuticals, Inc. net revenue has changed by 1 034 000 $ over the last period. The dynamics of net income of AVEO Pharmaceuticals, Inc. has changed by -10 618 000 $ in recent years. Graph of the financial report of AVEO Pharmaceuticals, Inc.. AVEO Pharmaceuticals, Inc. total revenue on the graph is shown in yellow. The value of all AVEO Pharmaceuticals, Inc. assets on the graph is shown in green.
Report date
Total revenue
Total revenue refers to the total receipts from sales of a given quantity of goods or services. It is the total income of a business and is calculated by multiplying the quantity of goods sold by the price of the goods.
and
Change (%)
Comparing current quartal report this year to quartal report last year.
Net income
Net income is an entity's income minus cost of goods sold, expenses and taxes for an accounting period.
and
Change (%)
Comparing current quartal report this year to quartal report last year.
31/03/2021
1 920 000 $
+19.18 % ↑
-22 122 000 $
-4085.946 % ↓
31/12/2020
886 000 $
-40.256 % ↓
-11 504 000 $
-152.727 % ↓
30/09/2020
3 600 000 $
-86.00148 % ↓
-8 393 000 $
-151.086 % ↓
30/06/2020
749 000 $
+6.54 % ↑
-7 306 000 $
-
30/09/2019
25 717 000 $
-
16 429 000 $
-
30/06/2019
703 000 $
-
-3 135 000 $
-
31/03/2019
1 611 000 $
-
555 000 $
-
31/12/2018
1 483 000 $
-
21 818 000 $
-
30/09/2018
2 467 000 $
-
-22 163 000 $
-
30/06/2018
433 000 $
-
4 004 000 $
-
31/03/2018
1 026 000 $
-
-8 988 000 $
-
31/12/2017
82 000 $
-
3 499 000 $
-
30/09/2017
4 614 000 $
-
-26 397 000 $
-
30/06/2017
351 000 $
-
-33 287 000 $
-
Show:
to
AVEO Pharmaceuticals, Inc. financial report charts
Dates of AVEO Pharmaceuticals, Inc. finance reports: 30/06/2017, 31/12/2020, 31/03/2021. Dates and dates of financial statements are established by the laws of the country where the company operates. The current date of the financial report of AVEO Pharmaceuticals, Inc. for today is 31/03/2021. Gross profit AVEO Pharmaceuticals, Inc. is the profit a company makes after deducting the costs of making and selling its products, or the costs of providing its services. Gross profit AVEO Pharmaceuticals, Inc. is -4 015 000 $
AVEO Pharmaceuticals, Inc. quarterly report dates
Cost of revenue AVEO Pharmaceuticals, Inc. is the total cost of producing and distributing of products and services of a company. Cost of revenue AVEO Pharmaceuticals, Inc. is 5 935 000 $ Total revenue AVEO Pharmaceuticals, Inc. refers to the total receipts from sales of a given quantity of goods or services. It is the total income of a business and is calculated by multiplying the quantity of goods sold by the price of the goods. Total revenue AVEO Pharmaceuticals, Inc. is 1 920 000 $ Operating income AVEO Pharmaceuticals, Inc. is an accounting figure that measures the amount of profit realized from a business's operations, after deducting operating expenses such as wages, depreciation and cost of goods sold (COGS). Operating income AVEO Pharmaceuticals, Inc. is -19 115 000 $
Net income AVEO Pharmaceuticals, Inc. is an entity's income minus cost of goods sold, expenses and taxes for an accounting period. Net income AVEO Pharmaceuticals, Inc. is -22 122 000 $ Current assets AVEO Pharmaceuticals, Inc. is a balance sheet item that represents the value of all assets that can reasonably expect to be converted into cash within one year. Current assets AVEO Pharmaceuticals, Inc. is 126 062 000 $ Total assets AVEO Pharmaceuticals, Inc. refers to the total amount of assets owned by a person or entity. Total assets AVEO Pharmaceuticals, Inc. is 127 436 000 $
31/03/2021
31/12/2020
30/09/2020
30/06/2020
30/09/2019
30/06/2019
31/03/2019
31/12/2018
30/09/2018
30/06/2018
31/03/2018
31/12/2017
30/09/2017
30/06/2017
Gross profit
Gross profit is the profit a company makes after deducting the costs of making and selling its products, or the costs of providing its services.
-4 015 000 $
-3 688 000 $
-2 260 000 $
-3 670 000 $
21 734 000 $
-1 908 000 $
-5 241 000 $
-3 718 000 $
-
-
-
-
-
-
Cost of revenue
Cost of revenue is the total cost of producing and distributing of products and services of a company.
5 935 000 $
4 574 000 $
5 860 000 $
4 419 000 $
3 983 000 $
2 611 000 $
6 852 000 $
5 201 000 $
-
-
-
-
-
-
Total revenue
Total revenue refers to the total receipts from sales of a given quantity of goods or services. It is the total income of a business and is calculated by multiplying the quantity of goods sold by the price of the goods.
1 920 000 $
886 000 $
3 600 000 $
749 000 $
25 717 000 $
703 000 $
1 611 000 $
1 483 000 $
2 467 000 $
433 000 $
1 026 000 $
82 000 $
4 614 000 $
351 000 $
Operating revenue
Operating revenue is revenue generated from a company's primary business activities. For example, a retailer produces revenue through merchandise sales, and a physician derives revenue from the medical services he/she provides.
-
-
-
-
25 717 000 $
703 000 $
1 611 000 $
1 483 000 $
2 467 000 $
433 000 $
980 000 $
82 000 $
4 614 000 $
351 000 $
Operating income
Operating income is an accounting figure that measures the amount of profit realized from a business's operations, after deducting operating expenses such as wages, depreciation and cost of goods sold (COGS).
-19 115 000 $
-12 696 000 $
-8 060 000 $
-7 407 000 $
18 850 000 $
-4 894 000 $
-7 696 000 $
-6 343 000 $
-5 412 000 $
-6 572 000 $
-7 030 000 $
-7 998 000 $
-2 153 000 $
-8 832 000 $
Net income
Net income is an entity's income minus cost of goods sold, expenses and taxes for an accounting period.
-22 122 000 $
-11 504 000 $
-8 393 000 $
-7 306 000 $
16 429 000 $
-3 135 000 $
555 000 $
21 818 000 $
-22 163 000 $
4 004 000 $
-8 988 000 $
3 499 000 $
-26 397 000 $
-33 287 000 $
R&D spending
Research and Development spending - cost of investigative activities to improve existing products and procedures or to lead to the development of new products and procedures.
-
-
-
-
-
-
-
-
5 160 000 $
4 887 000 $
5 404 000 $
5 676 000 $
4 666 000 $
6 881 000 $
Operating expense
An operating expense is an expenditure that a business incurs as a result of performing its normal business operations.
21 035 000 $
13 582 000 $
11 660 000 $
8 156 000 $
6 867 000 $
5 597 000 $
9 307 000 $
7 826 000 $
7 879 000 $
7 005 000 $
8 056 000 $
8 080 000 $
6 767 000 $
9 183 000 $
Current assets
Current assets is a balance sheet item that represents the value of all assets that can reasonably expect to be converted into cash within one year.
126 062 000 $
65 508 000 $
71 642 000 $
74 228 000 $
59 760 000 $
41 662 000 $
26 295 000 $
27 935 000 $
21 438 000 $
19 999 000 $
43 602 000 $
50 183 000 $
41 528 000 $
42 140 000 $
Total assets
Total assets refers to the total amount of assets owned by a person or entity.
127 436 000 $
66 912 000 $
73 022 000 $
75 602 000 $
59 760 000 $
41 662 000 $
26 507 000 $
27 935 000 $
21 442 000 $
20 006 000 $
43 613 000 $
50 198 000 $
41 711 000 $
42 492 000 $
Current cash
Current cash - the sum of all of the cash a company has on the date of report.
121 414 000 $
61 761 000 $
39 848 000 $
45 670 000 $
57 654 000 $
40 232 000 $
23 483 000 $
24 427 000 $
20 408 000 $
18 089 000 $
16 160 000 $
14 949 000 $
16 354 000 $
30 860 000 $
Current debt
Current debt is the portion of debt due within a year (12 months) and is listed as a current liability and part of net working capital.
-
-
-
-
20 831 000 $
18 885 000 $
18 891 000 $
18 117 000 $
4 256 000 $
2 388 000 $
586 000 $
-
4 920 000 $
3 055 000 $
Total cash
Total cash - the sum of all of the cash a company has on its books, including petty cash and funds on deposit in a bank.
-
-
-
-
-
-
-
-
20 408 000 $
18 089 000 $
26 995 000 $
33 525 000 $
37 409 000 $
40 127 000 $
Total debt
Total debt is a combination of both short-term and long-term debt. Short-term debts are those that must be paid back within a year. Long-term debt generally includes every liability that must be paid off in more than a year.
-
-
-
-
41 003 000 $
40 029 000 $
45 083 000 $
55 162 000 $
18 877 000 $
18 730 000 $
18 588 000 $
-
19 244 000 $
19 122 000 $
Debt ratio
Total debt to total assets - is a financial ratio that indicates the percentage of a company's assets that are provided via debt.
-
-
-
-
68.61 %
96.08 %
170.08 %
197.47 %
88.04 %
93.62 %
42.62 %
-
46.14 %
45 %
Shareholders equity
Shareholder's equity (SE) is the owner's claim after subtracting total liabilities from total assets.
72 448 000 $
35 294 000 $
40 223 000 $
48 052 000 $
18 757 000 $
1 633 000 $
-18 576 000 $
-27 227 000 $
-60 392 000 $
-45 445 000 $
-50 245 000 $
-40 763 000 $
-44 574 000 $
-19 330 000 $
Cash flow
Cash flow is the net amount of cash and cash-equivalents being transferred into and out of a business.
-
-
-
-
18 919 000 $
-6 011 000 $
-8 456 000 $
-6 617 000 $
-2 807 000 $
-9 084 000 $
-6 518 000 $
-3 749 000 $
-2 968 000 $
-7 039 000 $
Last revenue report of AVEO Pharmaceuticals, Inc. was 31/03/2021. According to last financial report total revenue in AVEO Pharmaceuticals, Inc. was 1 920 000 US dollar and changed by +19.18% since last year. Net income in AVEO Pharmaceuticals, Inc. was -22 122 000 $ in last quartal, net income changes to -4085.946%.
Current cash AVEO Pharmaceuticals, Inc. - the sum of all of the cash a company has on the date of report. Current cash AVEO Pharmaceuticals, Inc. is 121 414 000 $
AVEO Pharmaceuticals, Inc. stocks data
AVEO stock price
AVEO Pharmaceuticals, Inc. stock price today, AVEO stock quote.
